Compare Cytokinetics Inc (CYTK) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ON Holding AG — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while ON Holding AG trades at $33.95 (market cap $11.38B). The key difference: ON Holding AG is the larger of the two by market cap, and ON Holding AG is more actively traded (13,732,872 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and ON Holding AG for 22 Days on average.
| CYTK | ONON | |
|---|---|---|
Market Cap | $8.62B | $11.38B |
Volume | 2,594,626 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $50.63 |
52-Week Low | $54.76 | $26.76 |
Typical Hold Time | 19 Days | 22 Days |
Enterprise Value | $8.72B | $10.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
ONON trades at $33.22, up 0.27% with a bullish technical outlook supported by moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $0.44 exceeding the $0.42 consensus. Strong fundamentals include 64.8% gross margins and 23.95% ROE, while analyst sentiment remains positive with 74% buy ratings and a $42.26 price target representing 27% upside potential.
The stock offers growth potential through premium store expansion and new sports category launches, supported by a $1 billion buyback program through 2029. Key risks include high valuation multiples (P/E 24.02, P/S 5.67) and potential execution challenges in achieving ambitious 2029 targets of CHF 5.6 billion in sales. Recent investor day enthusiasm must be balanced against competitive pressures in the athletic footwear market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
